I

InSite Clinical Research | DeSoto, TX

Research site
(Unclaimed)
Location
941 York Drive Street 205, DeSoto, Texas, United States of America

Site insights

Top conditions

Top treatments

Buprenorphine
KarXT
Troriluzole
Lurasidone
Iclepertin
Daridorexant
LY03010
Aripiprazole
Brexpiprazole
SPN-810

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 77 total trials

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: Iclepertin

This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in d...

Active, not recruiting
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Locations recently updated

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.

Enrolling
Bipolar Disorder
Drug: Placebo
Drug: BHV-7000

The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of...

Active, not recruiting
Moderate to Severe Opioid-use Disorder
Drug: Transmucosal Buprenorphine
Drug: Extended-release Buprenorphine

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Active, not recruiting
Schizophrenia
Drug: Iclepertin
Drug: Placebo

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole
Locations recently updated

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult...

Enrolling
Schizophrenia
Drug: LB-102

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive d...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

Trial sponsors

Pfizer logo
Indivior logo
Boehringer Ingelheim logo
Otsuka logo
Biohaven logo
Karuna Therapeutics logo
Sumitomo Pharma logo
Bristol-Myers Squibb (BMS) logo
Biohaven logo
Idorsia Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems